Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3563278, 6 pages
https://doi.org/10.1155/2017/3563278
Research Article

Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?

1Department of Biomedical Sciences and Biotechnologies, 2nd Pediatric Clinic, University of Cagliari, Cagliari, Italy
2Pediatric Clinic, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
3Pediatrics, Department of Medicine, Surgery, and Dentistry “Schola Medica Salernitana”, University of Salerno, Baronissi, Salerno, Italy
4Pediatrics Unit, AORN Santobono-Pausilipon, Naples, Italy
5Mediterranean Institute for Transplantation & Advanced Specialized Therapies (ISMETT), Palermo, Italy
6Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany

Correspondence should be addressed to Roberto Antonucci; ti.ssinu@iccunotnar

Received 11 September 2017; Revised 31 October 2017; Accepted 6 November 2017; Published 27 November 2017

Academic Editor: Haruki Komatsu

Copyright © 2017 Maria Grazia Clemente et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Kerkar and G. Yanni, “'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review,” Journal of Autoimmunity, vol. 66, pp. 17–24, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. A. W. Lohse, P. Obermayer-Straub, G. Gerken et al., “Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease - Possible association with a steroid-resistant transplant rejection episode,” Journal of Hepatology, vol. 31, no. 1, pp. 149–155, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. Banff Working Group, A. J. Demetris, O. Adeyi et al., “Liver biopsy interpretation for causes of late liver allograft dysfunction,” Hepatology, vol. 44, no. 2, pp. 489–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. Clemente and K. Schwarz, “Hepatitis: General principles,” Pediatrics in Review, vol. 32, no. 8, pp. 333–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Miyakawa, E. Kitazawa, K. Kikuchi et al., “Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C,” Autoimmunity, vol. 33, no. 1, pp. 23–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Aguilera, I. Wichmann, J. M. Sousa et al., “Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation,” Clinical & Experimental Immunology, vol. 126, no. 3, pp. 535–539, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Huguet, J. Vinh, C. Johanet et al., “Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation,” Annals of the New York Academy of Sciences, vol. 1109, pp. 345–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Inui, T. Sogo, H. Komatsu, H. Miyakawa, and T. Fujisawa, “Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation,” Liver Transplantation, vol. 11, no. 5, pp. 504–507, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Sacher, P. Blümel, H. Thaler, and M. Manns, “Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies,” Journal of Hepatology, vol. 10, no. 3, pp. 364–369, 1990. View at Publisher · View at Google Scholar · View at Scopus
  10. M. P. Manns, K. J. Griffin, L. C. Quattrochi et al., “Identification of cytochrome P450IA2 as a human autoantigen,” Archives of Biochemistry and Biophysics, vol. 280, no. 1, pp. 229–232, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Clemente, P. Obermayer-Straub, A. Meloni et al., “Cytochrome P450 1A2 Is a Hepatic Autoantigen in Autoimmune Polyglandular Syndrome Type 1,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 5, pp. 1353–1361, 1997. View at Publisher · View at Google Scholar
  12. M. G. Clemente, A. Meloni, P. Obermayer-Straub, F. Frau, M. P. Manns, and S. De Virgiliis, “Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1,” Gastroenterology, vol. 114, no. 2, pp. 324–328, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Gebre-Medhin, E. S. Husebye, J. Gustafsson et al., “Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I,” FEBS Letters, vol. 412, no. 3, pp. 439–445, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Obermayer-Straub, J. Perheentupa, S. Braun et al., “Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy,” Gastroenterology, vol. 121, no. 3, pp. 668–677, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Lintas, M. Cappa, D. Comparcola, V. Nobili, and A. Fierabracci, “An 8-year-old boy with autoimmune hepatitis and Candida onychosis as the first symptoms of autoimmune polyglandular syndrome (APS1): Identification of a new homozygous mutation in the autoimmune regulator gene (aire),” European Journal of Pediatrics, vol. 167, no. 8, pp. 949–953, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Meloni, N. Willcox, A. Meager et al., “Autoimmune polyendocrine syndrome type 1: An extensive longitudinal study in Sardinian patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 4, pp. 1114–1124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bourdi, D. Larrey, J. Nataf et al., “Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis,” The Journal of Clinical Investigation, vol. 85, no. 6, pp. 1967–1973, 1990. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Salcedo, J. Vaquero, R. Baares et al., “Response to steroids in de novo autoimmune hepatitis after liver transplantation,” Hepatology, vol. 35, no. 2, pp. 349–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. M. G. Clemente, P. Vajro, M. P. Musu, E. Ciccimarra, C. Mandato, and S. De Virgiliis, “Evaluation of non organ specific autoantibodies in children transplanted for non-autoimmune liver diseases,” Gastroenterology, vol. 120, no. 5, pp. A213–A214, 2001. View at Publisher · View at Google Scholar
  20. D. Vergani and G. Mieli-Vergani, “Autoimmunity after liver transplantation,” Hepatology, vol. 36, no. 2, pp. 271–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. U. D. Ekong, P. McKiernan, M. Martinez et al., “Long-term outcomes of de novo autoimmune hepatitis in pediatric liver transplant recipients,” Pediatric Transplantation, vol. 21, no. 6, 2017. View at Publisher · View at Google Scholar
  22. J. G. O'Leary, J. Cai, R. Freeman et al., “Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts,” American Journal of Transplantation, vol. 16, no. 2, pp. 603–614, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Aguilera, J. M. Sousa, F. Gavilán, A. Bernardos, I. Wichmann, and A. Nuñez-Roldán, “Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation,” Liver Transplantation, vol. 10, no. 9, pp. 1166–1172, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Manns, U. Zanger, G. Gerken et al., “Patients with type ii autoimmune hepatitis express functionally intact cytochrome P‐450 db1 that is inhibited by LKM‐1 autoantibodies in vitro but not in vivo,” Hepatology, vol. 12, no. 1, pp. 127–132, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. D. A. Flockhart, “Drug Interactions and the Cytochrome P450 System: The Role of Cytochrome P450 2C19,” Clinical Pharmacokinetics, vol. 29, no. 1, pp. 45–52, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. P. H. Beaune and S. Lecoeur, “Immunotoxicology of the liver: adverse reactions to drugs,” Journal of Hepatology, vol. 26, suppl. 2, pp. 37–42, 1997. View at Publisher · View at Google Scholar